| Date |
Event |
Presentation |
Speakers |
|
October 24, 2015
|
19th International Meeting of the European Society of Gynaecological Oncology (ESGO 2015)
|
Parallel: Challenges in the Management of Cervical Cancer
|
Pedro T. Ramirez
|
|
|
|
Fellows’ Seminar: Tips and tricks in pelvic laparoscopic surgery & ESGO Quiz
|
Pedro T. Ramirez
|
|
April 11, 2014
|
6th Annual Asian Oncology Summit and 10th Annual Conference of the Organisation for Oncology and Translational Research (OOTR)
|
6th Annual Asian Oncology Summit and 10th Annual Conference of the Organisation for Oncology and Translational Research (OOTR)
|
Rakesh Kumar
|
|
March 19, 2014
|
3rd Neurological Biomarkers
|
Chairperson's Introduction
|
Andreas Jeromin
|
|
October 28, 2013
|
Tumor Immunology and Immunotherapy
|
TNFalpha and TLR3/4 induced necrosis pathway
|
Xiaodong Wang
|
|
May 31, 2013
|
ASCO Annual Meeting 2013
|
Management of Chronic Lymphocytic Leukemia (M10)
|
William G. Wierda
|
|
|
|
Education Sessions
|
Anas Younes
|
|
|
|
Education Sessions
|
John de Groot
|
|
|
|
Special Session
|
Razelle Kurzrock, Gabriel N Hortobagyi
|
|
|
|
Education Sessions
|
Robert L. Coleman
|
|
|
|
Educations Sessions
|
Jeffrey E Gershenwald, Stanley Hamilton
|
|
April 6, 2013
|
AACR Annual Meetings
|
Drug Discovery in Industry, Academia, and Government: What Is the Track Record?
|
Michael A. White
|
|
|
|
Clinical Trial Design in the Genomic Era Co-Chairpersons: Donald A. Berry, The University of Texas MD Anderson Cancer Center, Houston, TX, and George W. Sledge, Jr., Stanford University School of Medicine, Stanford, CA
|
Donald Berry
|
|
|
|
Rational Combination Therapies in Cancer Chairperson: Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX
|
Gordon Mills
|
|
|
|
Bridging the Gap Between Clinical Research and Laboratory Investigation: Utilizing Presurgical Clinical Trials to Investigate Anti-CTLA-4 Immunotherapy Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX
|
Padmanee Sharma
|
|
|
|
Whole Body Metabolism and Cancer Chairperson: Philipp E. Scherer, UT Southwestern Medical Center, Dallas, TX
|
Philipp Scherer
|
|
|
|
Tumor-Secreted Factors Chairperson: David C. Lyden, Weill Cornell Medical College of Cornell University, New York, NY
|
George A. Calin
|
|
|
|
Identifying Novel Redox Signaling Pathways for Cancer Chemoprevention: From Fly to the Mouse Garth Powis, The University of Texas MD Anderson Cancer Center, Houston, TX
|
Garth Powis
|
|
|
|
PAK Family of Kinases in Human Cancer: Past, Present, and Future Rakesh Kumar, George Washington University, Washington, DC
|
Rakesh Kumar
|
|
March 4, 2012
|
"Cellular Oncology" new insights leading to clinical advancement"
|
"Cellular Oncology" new insights leading to clinical advancement"
|
William F. Symmans
|
|
November 18, 2011
|
16th Annual Perspectives In Thoracic Oncology
|
New insights in the management of mesothelioma
|
Anne Tsao
|
|
July 6, 2011
|
3rd WIN Symposium
|
CONCURRENT WORKSHOPS | Workshop of the WIN Consortium Committee on standardization of biobanking and molecular analyses of biopsies in clinical trials (open to the public)
|
STANLEY HAMILTON, Ignacio I. Wistuba
|
|
|
|
ROUND TABLE - PANEL OF EXPERTS - FORUM OF OPEN DISCUSSION WITH ATTENDEES | Monotherapies or combined therapeutics? Clinically addressing the complexity of molecular pathways in cancer: How can we develop the most relevant combination beyond individual Pharma/Biotech pipelines: a risk sharing approach for the benefit of the patient
|
JOHN MENDELSOHN
|
|
|
|
KEYNOTE LECTURE | Challenges and opportunities in personalized cancer therapy and cooperation between the Pharmaceutical Industry and Academia. The WIN Consortium model and operational goals
|
JOHN MENDELSOHN
|
|
|
|
SESSION 4 | STRATEGIC ALLIANCES TO FIGHT CANCER
|
JOHN MENDELSOHN
|
|
|
|
Using biomarkers prospectively in adaptive trials
|
Donald Berry
|
|
|
|
SESSION 7 | STRATEGIES TO IMPROVE EFFICIENCY OF CLINICAL TRIALS
|
Donald Berry
|
|
|
|
CONCURRENT WORKSHOPS | Workshop of the WIN Consortium Scientific Committee on the design of clinical trials, data processing and access (open to the public)
|
Razelle Kurzrock, Donald Berry
|
|
|
|
CONCLUSION | THE URGENT NEED FOR INCREASED ACCESS OF PATIENTS FROM DIVERSE POPULATIONS TO INNOVATIVE CLINICAL TRIALS
|
JOHN MENDELSOHN
|
|
|
|
General Assembly of the WIN Consortium (business meeting, restricted to members and open to non members by request and invitation only)
|
JOHN MENDELSOHN
|
|
February 17, 2011
|
Mayo Clinic World Robotics Symposium in Gynecology
|
Robotic Pelvic Lymphadenectomy
|
Pedro T. Ramirez
|
|
|
|
Robotic Radical Trachelectomy for Fertility-Preservation
|
Pedro T. Ramirez
|
|
February 12, 2011
|
Cancer Control by Tumor Suppressors and Immune Effectors (J8)
|
Harnessing the Cell Biology of Dendritic Cells against Cancer (Joint) | Plasmacytoid DC in Cancer
|
Yong-Jun Liu
|
|
September 30, 2010
|
Third AACR Conference on The Science of Cancer Health Disparities
|
Educational Session 2: The Chronic Disease Prevention Model: It's Time to Think Strategically
|
Elisabeth Martinez
|
|
|
|
Quantitative epigenomics for epidemiology research
|
Jean-Pierre Issa
|
|
September 30, 2010
|
Third AACR Conference on the Science of Cancer Health Disparities in Racial / Ethnic Minorities and the Medically Underserved
|
The Chronic Disease Prevention Model: It's Time to Think Strategically
|
Elisabeth Martinez
|
|
|
|
Quantitative epigenomics for epidemiology research
|
Jean-Pierre Issa
|
|
September 27, 2010
|
25th Annual Critical Issues in Tumor Microenvironment, Angiogenesis and Metastasis: from Bench to Bedside to Biomarkers
|
Therapy of Cancer Metastasis: Attacking the Stroma
|
Isaiah J. Fidler
|
|
|
|
The Biology of Cancer Metastasis
|
Isaiah J. Fidler
|
|
July 15, 2010
|
Breast Cancer: Current Controversies | New Horizons
|
Surgery Issues After Preoperative Therapy
|
Funda Meric Bernstam
|
|
|
|
B. Managing the Extra-Axillary Sentinel Node and Positive Internal Mammary Nodes
|
Funda Meric Bernstam
|
|
April 10, 2010
|
Practical Updates in Oncology
|
Therapeutic Options in Ovarian Cancer
|
Robert L. Coleman
|
|
|
|
Advances in Chronic Lymphocytic Leukemia
|
William G. Wierda
|
|
|
|
Targeted Therapies for Gastrointestinal Malignancies
|
Cathy Eng
|
|
|
|
Treatment Advances in SCLC and NSCLC
|
Joan H Schiller
|
|
|
|
Lunch/Ethics Lecture
|
Michael S Ewer
|
|
February 19, 2010
|
Eighth International Symposium on Supportive Care in Oncology: Cancer Management in the Era of Targeted Agents
|
Nutrition and Supplements
|
Maria Petzel
|
|
|
|
Management of Toxicities Associated With Antivascular Agents
|
Michael S Ewer
|
|
February 11, 2010
|
Second Annual Conference The Sixth Vital Sign: What Every Oncologist Should Know About Molecular Oncology: Applications to Patient Care
|
Rare Tumors: A Personalized Therapy Approach With a Case History
|
Razelle Kurzrock
|
|
February 11, 2010
|
5th Annual Symposium on PET/CT and Molecular Imaging
|
Pick Your Poison with Bone Metastases: MDP or FDG?
|
Homer A. Macapinlac
|
|
|
|
Evaluating Pelvic Tumors
|
Homer A. Macapinlac
|
|
|
|
Imaging "The Prodigal Tumors": PET and Pancreatic, Hepatic, Small Bowel, Renal, Adrenal, and Metastastic Cancers
|
Homer A. Macapinlac
|
|
|
|
PET/CT for Infection: Blessing or a Curse
|
Homer A. Macapinlac
|
|
January 29, 2010
|
9th Annual UCSF Clinical Cancer Update
|
TBA
|
Massimo Cristofanilli
|
|
January 21, 2010
|
2010 DERMATOLOGY FOUNDATION CLINICAL SYMPOSIA: ADVANCES IN DERMATOLOGY
|
IV. Surgical Reconstruction: How We Do It
|
Tri H. Nguyen
|
|
|
|
Surgical Pearls: When Simple is Better
|
Tri H. Nguyen
|
|
January 21, 2010
|
7th Annual Natural Supplements: An Evidence-Based Update
|
A. Diabetes and Metabolic Syndrome: An Integrative Approach
|
Victor Sierpina
|
|
November 12, 2009
|
Sixth International Conference - Revitalizing Cancer Care: Comprehensive Interdisciplinary Programs and Whole Systems Research
|
Keynote Lecture: Whole Systems Research in Integrative Oncology: What is It? Why Do We Need It?
|
Lorenzo Cohen
|
|
|
|
d. Massage Therapy
|
Sat-Siri Sumler
|
|
|
|
Theory/Practice
|
Moshe Frenkel
|
|
|
|
1) Preferred Abstracts (5) Basic
|
Peiying Yang
|
|
|
|
Whole Systems Into Practice: Summary and Future Visions
|
David I Rosenthal, Moshe Frenkel
|
|
November 6, 2009
|
Translating Scientific Advances Into Clinical Care for Cancer
|
Multiple Myeloma
|
Robert Z. Orlowski
|
|
October 2, 2009
|
13th Annual Fall Oncology Conference: Clinical Challenges in Cancer Medicine
|
State-of-the-Art Treatment in Sarcoma
|
Robert S. Benjamin
|
|
|
|
PRO
|
Cathy Eng
|
|
|
|
PRO
|
Robert Coleman
|
|
|
|
Treatment Options for Patients With Platinum-Sensitive and Platinum-Resistant Recurrent Ovarian Cancer
|
Robert Coleman
|
|
|
|
Complications of Antiangiogenic Therapy
|
Cathy Eng
|
|
October 1, 2009
|
6TH ANNUAL MEETING OF THE INTERNATIONAL SOCIETY OF GASTROINTESTINAL ONCOLOGY (ISGIO)
|
Panel Discussion With Interactive Q/A
|
Sushovan Guha
|
|
|
|
Case Presentation 2: Locally Advanced (Radiotherapy vs. Chemotherapy)
|
Gauri Varadhachary
|
|
|
|
Panel Discussion With Interactive Q/A
|
Sushovan Guha
|
|
|
|
A Novel Small Molecule Inhibitor of Protein Kinase D Blocks Pancreatic Cancer Growth In Vivo
|
Sushovan Guha
|
|
|
|
Prognostic Factors of Rectal and Anal Cancer Outcomes
|
Prajnan Das
|
|
|
|
Panel Discussion With Interactive Q/A
|
Ju-Seog Lee
|
|
|
|
Molecular Biology: East and West
|
Ju-Seog Lee
|
|
September 24, 2009
|
Track 3:Advancing Cancer Therapy : Inaugural Circulating Tumor Cells
|
The Clinical Utility of Circulating Tumor Cell Analysis: What Have We Learned So Far?
|
Beverly C. Handy
|
|
September 23, 2009
|
TRACK 1: Optimizing Clinical Trials : Third Annual Adaptive Clinical Trial Designs
|
Personalized Medicine: Using Biomarker Signatures to Predict Response to New Therapies
|
J. Kyle Wathen
|
|
June 9, 2009
|
Cell and Tissue-Based Assays for HTS
|
A Novel Platform for High-Throughput Gene Expression Profiling
|
Andreas Jeromin
|
|
February 3, 2009
|
Cancer Health Disparities
|
PLENARY SESSION 2: INJECTING CULTURE INTO THE ATTACK ON CANCER
|
Amelie G Ramirez
|
|
|
|
CONCURRENT SESSIONS
|
M Kristen Peek
|
|
January 26, 2009
|
Biomarker Assay Development
|
Circulating Tumor Cell Assays: A Prognostic and Predictive Factor For Breast, Prostate And Colon Cancer
|
Herbert A Fritsche
|
|
January 26, 2009
|
Translational Cancer Medicine
|
Circulating Tumor Cell Assays: A Prognostic and Predictive Factor For Breast, Prostate And Colon Cancer
|
Herbert A Fritsche
|
|
January 21, 2009
|
Advances in Prostate Cancer Research
|
SESSION 3: APOPTOSIS
|
Xiaodong Wang
|
|
December 4, 2008
|
BIT Life Sciences 2nd Annual World Congress of Gene-2008 (WCG 2008)
|
Application of New Proteomics Technologies to Drug Discovery : Track 1-3
|
Yingming Zhao
|
|
|
|
Title: TBD:Track 2-2
|
Dihua Yu
|
|
|
|
Feedstock and Enzyme Improvement for Bioenergy : Track 5-1
|
Joshua S. Yuan
|
|
November 23, 2008
|
Advanced Technology in Radiation Oncology
|
Inhibition Of XIAP Facilitates TRAIL Induced Apoptosis And Improves Survival In A Bioluminescent Glioma Xenograft Model.
|
Vinay K Puduvalli
|
|
November 21, 2008
|
The 13th Annual Scientific Meeting of the Society for Neuro-Oncology
|
Enzastaurin (ENZ) Versus Lomustine (CCNU) In The Treatment Of Recurrent, Intracranial Glioblastoma (GBM): A Phase III Study.
|
Vinay K Puduvalli
|
|
|
|
Imaging Glioblastoma Progression During Anti-VEGF Therapy.
|
John de Groot
|
|
November 17, 2008
|
BIO-Europe 2008
|
Critical Issues to Consider when Entering the U.S. Market and Partnering with U.S. Companies
|
Steve Bryant
|
|
November 6, 2008
|
The 2008 Research Conference on Food, Nutrition, Physical Activity & Cancer
|
Omega-3 Fatty Acids and Cancer Prevention
|
Robert S. Chapkin
|
|
October 30, 2008
|
44th ASCO Annual Meeting
|
General Session IV: Molecular Markers of Response and Resistance to Angiogenesis Inhibitors
|
John Heymach
|
|
October 21, 2008
|
20th EORTC - NCI - AACR Symposium on "Molecular Targets and Cancer Therapeutics"
|
Workshop 1 Animal models in drug development
|
J. L. Abbruzzese
|
|
|
|
Plenary session 10 Challenges in the development of anti bodies and antibody conjugates
|
Chris H. Takimoto
|
|
June 27, 2008
|
American Society of Clinical Oncology
|
Welcome & Introductions
|
J. L. Abbruzzese
|
|
|
|
Program Commitee
|
J. L. Abbruzzese, Cathy Eng, Hagop M. Kantarjian
|
|
May 30, 2008
|
ASCO Annual'08 Meeting
|
breast cancer-- Postmenopausal Hormone Therapy: Friend or Foe? (M19)
|
Peter Ravdin
|
|
|
|
cancer genetics-- Single Nucleotide Polymorphisms, Clinical Trials, and Tobacco Research: Search for the Smoking Gun
|
Margaret R. Spitz
|
|
|
|
cancer prevention/epidemiology-- Single Nucleotide Polymorphisms, Clinical Trials, and Tobacco Research: Search for the Smoking Gun
|
Margaret R. Spitz
|
|
|
|
cancer prevention/epidemiology-- Postmenopausal Hormone Therapy: Friend or Foe? (M19)
|
Peter Ravdin
|
|
|
|
developmental therapeutics-- c-MET Inhibition for Cancer Treatment
|
Razelle Kurzrock
|
|
|
|
developmental therapeutics-- Issues in the Modulation of Angiogenesis Pathways (M10)
|
Roy S. Herbst
|
|
|
|
developmental therapeutics-- Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials?
|
Chris H. Takimoto
|
|
|
|
gastrointestinal (colorectal) cancer-- Advances in Anal Cancer Management (M01)
|
Cathy Eng
|
|
|
|
gastrointestinal (colorectal) cancer-- Intraperitoneal Treatment for Gastrointestinal Cancer: Role of Debulking and Chemotherapy
|
Cathy Eng
|
|
|
|
gastrointestinal (noncolorectal) cancer-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07A)
|
James C. Yao
|
|
|
|
gastrointestinal (noncolorectal) cancer-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07B)
|
James C. Yao
|
|
|
|
gastrointestinal (noncolorectal) cancer-- Intraperitoneal Treatment for Gastrointestinal Cancer: Role of Debulking and Chemotherapy
|
Cathy Eng
|
|
|
|
gastrointestinal (noncolorectal) cancer Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials?
|
Chris H. Takimoto
|
|
|
|
genitourinary cancer-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies CPO20A)
|
Paul Mathew
|
|
|
|
genitourinary cancer What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20B)
|
Paul Mathew
|
|
|
|
gynecologic cancer-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20)
|
Maurie Markman
|
|
|
|
lung cancer-- Therapeutic Modalities for “Small” Stage I Lung Cancers
|
Robert Timmerman
|
|
|
|
lymphoma and plasma cell disorders-- The Role of Maintenance Therapy in Follicular Lymphoma: Pros and Cons
|
Peter McLaughlin
|
|
|
|
patient and survivor care-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20)
|
Maurie Markman
|
|
|
|
patient and survivor care-- Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials?
|
Chris H. Takimoto
|
|
|
|
sarcoma/bone and soft tissue cancers-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12)
|
Shreyaskumar Patel
|
|
|
|
tumor biology-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12)
|
Shreyaskumar Patel
|
|
|
|
meet the professor sessions-- Advances in Anal Cancer Management (M01)
|
Cathy Eng
|
|
|
|
meet the professor sessions-- Issues in the Modulation of Angiogenesis Pathways (M10)
|
Roy S. Herbst
|
|
|
|
meet the professor sessions-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20)
|
Maurie Markman
|
|
|
|
meet the professor sessions-- Postmenopausal Hormone Therapy: Friend or Foe? (M19)
|
Peter Ravdin
|
|
|
|
meet the professor sessions-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12)
|
Shreyaskumar Patel
|
|
|
|
clinical problems in oncology-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07A)
|
James C. Yao
|
|
|
|
clinical problems in oncology-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07B)
|
James C. Yao
|
|
|
|
clinical problems in oncology-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20A)
|
Paul Mathew
|
|
|
|
clinical problems in oncology-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20B)
|
Paul Mathew
|
|
April 27, 2008
|
Phage Display of Antibodies and Peptides
|
Engineering Aglycosylated Antibodies with Effector Functions
|
George Georgiou
|
|
|
|
Ligand-Directed Vascular Targeting and Molecular Imaging
|
Renata Pasqualini
|
|
March 25, 2008
|
PATHWAY ANALYSIS
|
Non Coding RNAs Involvement in Cancer Predisposition and Tumor Development
|
George A. Calin
|
|
March 25, 2008
|
CANCER MOLECULAR MARKERS
|
Non Coding RNAs Involvement in Cancer Predisposition and Tumor Development
|
George A. Calin
|
|
January 18, 2008
|
Translational Research Program Stem Cell Symposium
|
Critique/Discussion
|
Wendy Woodward
|
|
|
|
Circulating Tumor Cells
|
Massimo Cristofanilli
|
|
|
|
Panel Discussion
|
Luka Milas
|
|
November 6, 2007
|
Chemotherapy Foundation Symposium XXV
|
SECOND & THIRD GENERATION TYROSINE KINASE INHIBITORS in CML
|
Hagop M. Kantarjian
|
|
|
|
AML IN THE ELDERLY: A PROBLEM WITH SOME SOLUTIONS
|
Hagop M. Kantarjian
|
|
|
|
UPDATE ON TREATMENT OPTIONS IN MDS AND AML
|
Guillermo Garcia-Manero
|
|
|
|
NOVEL THERAPIES FOR MANTLE CELL LYMPHOMA
|
Michael Wang
|
|
|
|
CP-4055, A NOVEL NUCELOSIDE ANALOG
|
Frank J. Giles
|
|
|
|
NILOTINIB: A HIGHLY SPECIFIC BCR-ABL INHIBITOR
|
Frank J. Giles
|
|
|
|
ROLE OF INTRAPERITONEAL DRUG DELIVERY IN THE MANAGEMENT OF OVARIAN CANCER
|
Maurie Markman
|
|
|
|
BIOMARKERS FOR OVARIAN CANCER
|
Robert C Bast
|
|
|
|
LAPATINIB/PACLITAXEL FOR INFLAMMATORY BREAST CANCER
|
Massimo Cristofanilli
|
|
|
|
RECENT CHANGES IN INCIDENCE AND MORTALITY IN THE US
|
Peter Ravdin
|
|
|
|
PHASE II STUDY OF RAD001 (EVEROLIMUS) AND DEPOT OCTREOTIDE IN ADVANCED LOW GRADE NEUROENDOCRINE CARCINOMA
|
Alexandria Phan
|
|
|
|
BEVACIZUMAB FOR MALIGNANT GLIOMAS: RESULTS AND FUTURE DIRECTIONS
|
Mark R. Gilbert
|
|
|
|
RANDOMIZED PHASE II TRIAL OF PACLITAXEL WITH OR WITHOUT STA 4783 IN METASTATIC MELANOMA
|
David Lawson
|
|
|
|
RANDOMIZED PHASE II TRIAL OF PACLITAXEL WITH OR WITHOUT STA 4783 IN METASTATIC MELANOMA
|
David Lawson
|
|
October 28, 2007
|
Third Annual Integrating Novel Agents With Radiotherapy in the Treatment of Solid Tumors Conference
|
Integration of Angiogenesis Inhibition With RT
|
Christopher Crane
|
|
October 20, 2007
|
Fourth Annual Fall Oncology Conference
|
Role of RT In the Management of Lung Cancer
|
Hak Choy
|
|
|
|
Special Topic: Update on the Current Management of Ovarian Cancer
|
Maurie Markman
|
|
October 16, 2007
|
Inaugural HDAC inhibitors: Meeting the Challenges of Chemical Development of HDAC Inhibitors Oct (16 -17)
|
MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT(11:10-16:30)
|
Madeleine Duvic
|
|
|
|
MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT: Panel Discussion- Are HDAC Inhibitors Proving Their Worth in the Clinic? (14:25-15:25)
|
Madeleine Duvic
|
|
October 11, 2007
|
Sixth International Colorectal Cancer Congress
|
Role of uPAR in Colorectal Cancer
|
Lee M Ellis
|
|
|
|
Unexpected Findings in Angiogenesis Research
|
Lee M Ellis
|
|
|
|
Should Anti-VEGF Therapy Continue Beyond Progession?
|
Lee M Ellis
|
|
|
|
Angiopoietin Inhibitors
|
Chris H. Takimoto
|
How We Rank